A Phase 2 interventional study of Irinotecan and Panitumumab in Colorectal Cancer, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-12.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies testing panitumumab in Colorectal Neoplasms — 7 open to participants now, 12 under way, 3 of them phase 3. Panitumumab · Colorectal Neoplasms.
Among the 90 studies testing panitumumab in Colorectal Neoplasms, this one is the 59th largest by enrollment of the 88 interventional ones that give a count, is one of 3 that started in 2002, is one of 60 in phase 2, and was the 5th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →7 of the 90 studies testing panitumumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
AbbVie · Sites in United States, Australia, Austria and 12 more countries
Ages 18+
R-Pharm · Sites in Russia
Ages 18+
UNICANCER · Sites in France
Ages 18+
Amgen · Sites in United States, Argentina, Australia and 32 more countries
Ages 18+
By country, each count listing its studies:
Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 68 · Phase 3 15 · Phase 4 1
First in 2000; this study’s year is marked. 3 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 43 is below the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 70 across the 88 interventional studies. Of the 67 that completed or were terminated, 30 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 90 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
40 studies in Colorectal Neoplasms by Amgen: 2 open now, 2 under way, 1 of them phase 3. Of 38 finished, 24 (63%) have results posted.
Among the 40 studies in Colorectal Neoplasms by Amgen, this one is the 27th largest by enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2002, is one of 16 in phase 2, and was the 4th registered.
Amgen’s Colorectal Neoplasms studies by the year they started, since 2002.
3 of the studies testing panitumumab in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03087071M.D. Anderson Cancer CenterPanitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer | 2027-01-31 |
| NCT05845450Gruppo Oncologico del Nord-OvestPre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) | 2027-05 |
| NCT07318389M.D. Anderson Cancer CenterASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer | 2027-11-14 |
Add all 3 to your calendar (.ics) → With an account.
Among the 90 studies testing panitumumab in Colorectal Neoplasms, from their registry updates:
Among Amgen’s 40 in Colorectal Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if panitumumab, in combination with irinotecan, leucovorin, and 5-fluorouracil (5-FU) is safe and efficacious in patients with metastatic colorectal cancer.
Indication Metastatic Colorectal Cancer Primary Objective To assess the safety of ABX-EGF in combination with the FOLFIRI regimen in subjects with metastatic colorectal cancer. (The primary objective in the original protocol was to assess progression free survival after treatment with ABX-EGF in combination with the Saltz regimen in subjects with metastatic colorectal cancer).
Secondary Objective(s) To assess the clinical efficacy of ABX-EGF in combination with the FOLFIRI regimen in subjects with metastatic colorectal cancer. (Secondary objectives in the original protocol were to assess safety and additional measures of the clinical efficacy of ABX-EGF in combination with the Saltz regimen in subjects with metastatic colorectal cancer).
To assess the pharmacokinetics (PK) of ABX-EGF in combination with the FOLFIRI regimen in subjects with metastatic colorectal cancer. (Secondary objectives in the original protocol were to assess the PK of ABX-EGF in combination with the Saltz regimen, and the PK of irinotecan (IR) and its active metabolite SN-38 when IR is given in combination with ABX-EGF, leucovorin (LV), and 5-fluorouracil (5-FU) in subjects with metastatic colorectal cancer)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any of the following within 6 months before the first study drug dose:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Panitumumab (2.5 mg/kg once weekly for up to 48 weeks or until disease progression, intolerable adverse event or other reason for discontinuation) in combination with irinotecan, 5-fluorouracil (5-FU)and leucovorin (IFL chemotherapy regimen)
Drug: Irinotecan · Biological: Panitumumab · Drug: 5-Fluorouracil · Drug: Leucovorin
Panitumumab (2.5 mg/kg once weekly until disease progression, intolerable adverse event or other reason for discontinuation) in combination with irinotecan/5-FU/leucovorin chemotherapy (the FOLFIRI regimen)
Drug: Irinotecan · Biological: Panitumumab · Drug: 5-Fluorouracil · Drug: Leucovorin
Part 1: 125 mg/m\^2 IV infusion once a week on weeks 1 through 4 of each 6-week treatment cycle. Part 2: 180 mg/m\^2 IV infusion every other week until disease progression or unable to tolerate.
Intravenous (IV) infusions of panitumumab 2.5 mg/kg once a week delivered in 6-week cycles.
Also known as: ABX-EGF
Part 1: IV bolus 500 mg/m\^2 on weeks 1 through 4 of each 6-week cycle. Part 2: IV bolus 400 mg/m\^2 and infusional 2400-3000 mg/m\^2 over 46 hours once every other week until disease progression or unable to tolerate.
Part 1: IV bolus 20 mg/m\^2 on weeks 1 through 4 of each 6-week cycle. Part 2: 400 mg/m\^2 every other week until disease progression or unable to tolerate.
Number of Participants With Grade 3 or Grade 4 Diarrhea (Part 2)
The number of participants with grade 3 or grade 4 diarrhea in Part 2 of the study. Grading of diarrhea followed the grading scale in Version 2.0 of the National Cancer Institute Common Toxicity Criteria (NCI CTC).
Time frame: Until disease progression (median 47 weeks)
Number of Participants With Grade 3 or Grade 4 Diarrhea (Part 1)
The number of participants with grade 3 or grade 4 diarrhea in Part 1 of the study. Grading of diarrhea followed the grading scale in Version 2.0 of the National Cancer Institute Common Toxicity Criteria (NCI CTC).
Time frame: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first
Number of Participants With an Objective Tumor Response (Part 2)
Objective tumor response (complete or partial) in Part 2 of the study, based on Response Evaluation Criteria in Solid Tumors (RECIST), where complete response = disappearance of all target lesions, partial response = ≥30% reduction in lesion size, progressive disease = ≥20% increase in tumor size; otherwise stable disease.
Time frame: Until disease progression (median 47 weeks)
Time to Disease Progression (Part 2)
Kaplan-Meier estimate of median time from the first dose of study drug to first observed disease progression or death if the death was due to disease progression (whichever comes first) in Part 2 of the study. Participants who had not progressed or died for reasons other than disease progression were censored at their last disease assessment date.
Time frame: From enrollment until death or diease progression. Maximum follow-up time was 16 months.
Progression-free Survival Time (Part 2)
Kaplan-Meier estimate of median time from enrollment to death or disease progression in Part 2 of the study. Participants who had not progressed and had not died were censored at their last disease assessment date.
Time frame: From enrollment until disease progression or death. Maximum follow-up time was 16 months.
Survival Time (Part 2)
Kaplan-Meier estimate of the median time from enrollment to death from any cause. Participants who did not die on study were censored at their last contact date.
Time frame: From enrollment until death. Maximum follow-up time was 16 months.
Number of Participants Who Died (Part 2)
The number of participants in Part 2 who died during the study.
Time frame: From enrollment until last contact. Maximum follow-up was 16 months.
Number of Participants With Objective Tumor Response (Part 1)
Objective tumor response (complete or partial) in Part 1 of the study, based on Response Evaluation Criteria in Solid Tumors (RECIST), where complete response = disappearance of all target lesions, partial response = ≥30% reduction in lesion size, progressive disease = ≥20% increase in tumor size; otherwise stable disease.
Time frame: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first
Progression-free Survival Time (Part 1)
Kaplan-Meier estimate of median time from enrollment to death or disease progression in Part 1 of the study. Participants who had not progressed and had not died were censored at their last disease assessment date.
Time frame: From enrollment until disease progression or death. Maximum follow-up time was 25 months.
Time to Disease Progression (Part 1)
Kaplan-Meier estimate of the median time from the first dose of study drug to disease progression or death if due to disease progression (whichever comes first) in Part 1 of the study. Participants who had not progressed or died for reasons other than disease progression were censored at their last disease assessment date.
Time frame: From enrollment until disease progression or death. Maximum follow-up time was 25 months.
Survival Time (Part 1)
Kaplan-Meier estimate of the median time from enrollment to death from any cause. Participants who did not die on study were censored at their last contact date.
Time frame: From enrollment until death. Maximum follow-up time was 25 months.
Time to Treatment Failure (Part 1)
Kaplan-Meier estimate of the median time from the date of first dose of panitumumab or chemotherapy to the date the decision was made to end treatment for any reason in Part 1 of the study.
Time frame: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first
Time to Initial Objective Tumor Response (Part 1)
Median time to first observed objective tumor response (complete or partial) among responders in Part 1 of the study.
Time frame: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first
Participants were enrolled from 19 Jul 2002 through 20 April 2004
| Milestone | Panitumumab With FOLFIRI | Panitumumab With IFL |
|---|---|---|
| Started | 0 | 19 |
| Completed | 0 | 14 |
| Not completed | 0 | 5 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Death | 0 | 2 |
| Withdrew: Other | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Milestone | Panitumumab With FOLFIRI | Panitumumab With IFL |
|---|---|---|
| Started | 24 | 0 |
| Completed | 16 | 0 |
| Not completed | 8 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Disease progression | 3 | 0 |
| Withdrew: Protocol-specified criteria | 1 | 0 |
| Withdrew: Other | 1 | 0 |
The number of participants with grade 3 or grade 4 diarrhea in Part 2 of the study. Grading of diarrhea followed the grading scale in Version 2.0 of the National Cancer Institute Common Toxicity Criteria (NCI CTC).
| Participants | Panitumumab With FOLFIRI |
|---|---|
| Number of Participants With Grade 3 or Grade 4 Diarrhea (Part 2) | 6 |
The number of participants with grade 3 or grade 4 diarrhea in Part 1 of the study. Grading of diarrhea followed the grading scale in Version 2.0 of the National Cancer Institute Common Toxicity Criteria (NCI CTC).
| Participants | Panitumumab With IFL |
|---|---|
| Number of Participants With Grade 3 or Grade 4 Diarrhea (Part 1) | 11 |
Objective tumor response (complete or partial) in Part 2 of the study, based on Response Evaluation Criteria in Solid Tumors (RECIST), where complete response = disappearance of all target lesions, partial response = ≥30% reduction in lesion size, progressive disease = ≥20% increase in tumor size; otherwise stable disease.
| Participants | Panitumumab With FOLFIRI |
|---|---|
| Number of Participants With an Objective Tumor Response (Part 2) | 8 |
Kaplan-Meier estimate of median time from the first dose of study drug to first observed disease progression or death if the death was due to disease progression (whichever comes first) in Part 2 of the study. Participants who had not progressed or died for reasons other than disease progression were censored at their last disease assessment date.
| weeks | Panitumumab With FOLFIRI |
|---|---|
| Time to Disease Progression (Part 2) | 47.3 (26.0 to NA) |
Kaplan-Meier estimate of median time from enrollment to death or disease progression in Part 2 of the study. Participants who had not progressed and had not died were censored at their last disease assessment date.
| weeks | Panitumumab With FOLFIRI |
|---|---|
| Progression-free Survival Time (Part 2) | 41.1 (26.0 to NA) |
Kaplan-Meier estimate of the median time from enrollment to death from any cause. Participants who did not die on study were censored at their last contact date.
| weeks | Panitumumab With IFL |
|---|---|
| Survival Time (Part 2) | 73.1 (59.4 to NA) |
The number of participants in Part 2 who died during the study.
| participants | Panitumumab With FOLFIRI |
|---|---|
| Number of Participants Who Died (Part 2) | 6 |
Objective tumor response (complete or partial) in Part 1 of the study, based on Response Evaluation Criteria in Solid Tumors (RECIST), where complete response = disappearance of all target lesions, partial response = ≥30% reduction in lesion size, progressive disease = ≥20% increase in tumor size; otherwise stable disease.
| Participants | Panitumumab With IFL |
|---|---|
| Number of Participants With Objective Tumor Response (Part 1) | 9 |
Kaplan-Meier estimate of median time from enrollment to death or disease progression in Part 1 of the study. Participants who had not progressed and had not died were censored at their last disease assessment date.
| weeks | Panitumumab With IFL |
|---|---|
| Progression-free Survival Time (Part 1) | 24.3 (19.0 to 36.0) |
Kaplan-Meier estimate of the median time from the first dose of study drug to disease progression or death if due to disease progression (whichever comes first) in Part 1 of the study. Participants who had not progressed or died for reasons other than disease progression were censored at their last disease assessment date.
| weeks | Panitumumab With IFL |
|---|---|
| Time to Disease Progression (Part 1) | 35.0 (21.7 to 72.0) |
Kaplan-Meier estimate of the median time from enrollment to death from any cause. Participants who did not die on study were censored at their last contact date.
| weeks | Panitumumab With IFL |
|---|---|
| Survival Time (Part 1) | 73.1 (59.4 to NA) |
Kaplan-Meier estimate of the median time from the date of first dose of panitumumab or chemotherapy to the date the decision was made to end treatment for any reason in Part 1 of the study.
| Weeks | Panitumumab With IFL |
|---|---|
| Time to Treatment Failure (Part 1) | 24.3 (7.9 to 36.0) |
Median time to first observed objective tumor response (complete or partial) among responders in Part 1 of the study.
| weeks | Panitumumab With IFL |
|---|---|
| Time to Initial Objective Tumor Response (Part 1) | 5.9 (5.4 to 11.3) |
Collected over First dose through maximum of safety FU or 30 days after last dose (median 47 weeks follow-up). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Panitumumab Plus IFL | — | 12/19 (63.2%) | 19/19 (100%) |
| Panitumumab Plus FOLFIRI | — | 11/24 (45.8%) | 24/24 (100%) |
| Event | Panitumumab Plus IFL | Panitumumab Plus FOLFIRI |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 8/19 | 1/24 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/19 | 0/24 |
| Abdominal painGastrointestinal disorders | 2/19 | 0/24 |
| DehydrationMetabolism and nutrition disorders | 2/19 | 0/24 |
| Chest painGeneral disorders | 0/19 | 2/24 |
| CellulitisInfections and infestations | 0/19 | 2/24 |
| SepsisInfections and infestations | 0/19 | 2/24 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/19 | 2/24 |
| Ileus paralyticGastrointestinal disorders | 1/19 | 0/24 |
| Rectal haemorrhageGastrointestinal disorders | 1/19 | 0/24 |
| Event | Panitumumab Plus IFL | Panitumumab Plus FOLFIRI |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 16/19 | 19/24 |
| FatigueGeneral disorders | 16/19 | 19/24 |
| RashSkin and subcutaneous tissue disorders | 16/19 | 19/24 |
| NauseaGastrointestinal disorders | 13/19 | 15/24 |
| AnorexiaMetabolism and nutrition disorders | 7/19 | 13/24 |
| VomitingGastrointestinal disorders | 5/19 | 11/24 |
| Abdominal painGastrointestinal disorders | 8/19 | 8/24 |
| StomatitisGastrointestinal disorders | 8/19 | 6/24 |
| ConstipationGastrointestinal disorders | 7/19 | 10/24 |
| AlopeciaSkin and subcutaneous tissue disorders | 6/19 | 10/24 |
| Age Continuous(Years) | Panitumumab With IFL | Panitumumab With FOLFIRI | Total |
|---|---|---|---|
| Mean | 56.6 ± 12.1 | 60.7 ± 15.0 | 58.9 ± 13.8 |
| Sex: Female, Male(Participants) | Panitumumab With IFL | Panitumumab With FOLFIRI | Total |
|---|---|---|---|
| Female | 3 | 10 | 13 |
| Male | 16 | 14 | 30 |
| Race/Ethnicity, Customized(Participants) | Panitumumab With IFL | Panitumumab With FOLFIRI | Total |
|---|---|---|---|
| Asian | 1 | 1 | 2 |
| Black or African American | 4 | 3 | 7 |
| Hispanic or Latino | 1 | 2 | 3 |
| White or Caucasian | 13 | 18 | 31 |
| Other | 0 | 0 | 0 |
No study locations are listed for this record.
The record gives a start of Jul 2002, a primary completion of Feb 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2011, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Panitumumab